Unocon is one of the leading enterprises in China pharmaceutical industry, with total assets of 20 billion yuan and employees of 1.8 million. Listed companies in Hong Kong (0 1093. HK) The market value is HK$ 40 billion. It is one of the well-known pharmaceutical listed companies in Hong Kong, and a constituent stock of Hong Kong Hang Seng Red Chip Index.
Unocom has six business segments: raw materials, patented drugs, innovative drugs, anti-tumor drugs, pharmaceutical commerce and big health, mainly engaged in the research and development, production and sales of drugs and related products. Products mainly include antibiotics, vitamins, cardiovascular and cerebrovascular diseases, antipyretic and analgesic drugs, digestive system drugs, anti-tumor drugs, Chinese patent medicines and other seven series of nearly 1,000 varieties.
Unocom has more than 30 subsidiaries in Hebei, Kyrgyzstan, Shanxi, Liaoning, Shandong, Jiangsu and Hong Kong. Among them, Hong Kong Shi Yao Group Co., Ltd., a holding subsidiary of Hong Kong, is the first overseas listed company in China pharmaceutical industry, one of the largest pharmaceutical listed companies in Hong Kong at present, and one of the constituent stocks of Hong Kong Hang Seng Red Chip Index. It has been rated as one of the outstanding listed companies in Asia 100 with turnover less than 1 00 million dollars by the world-famous Forbes magazine twice in a row.
See official website, Unacon: Unacon for details.
/About _us.aspx